Current position of 5HT(3) antagonists and the additional value of NK(1) antagonists; a new class of antiemetics

por de Wit, R
Publicado 2003

Description of an antique radium-goblet; a dangerous curiosity.

por De Wit, R, De Roo, T
Publicado 1974

Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer

por van Weerden, W M, Bangma, C, de Wit, R
Publicado 2009

Oral piritrexim, an effective treatment for metastatic urothelial cancer.

por de Wit, R., Kaye, S. B., Roberts, J. T., Stoter, G., Scott, J., Verweij, J.
Publicado 1993

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.

por de Wit, R., Kruit, W. H., Stoter, G., de Boer, M., Kerger, J., Verweij, J.
Publicado 1998

Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.

por de Wit, R., Beijnen, J. H., van Tellingen, O., Schellens, J. H., de Boer-Dennert, M., Verweij, J.
Publicado 1996

Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours follo...

por de Wit, R, de Boer, A C, vd Linden, G H M, Stoter, G, Sparreboom, A, Verweij, J
Publicado 2001

Reply: Granisetron vs ondansetron: is it a question of duration of 5-HT(3) receptor blockade?

por de Wit, R, Stoter, G, Sparreboom, A, Verweij, J, de Boer, A C, vd Linden, G H M
Publicado 2002

Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists.

por de Boer-Dennert, M., de Wit, R., Schmitz, P. I., Djontono, J., v Beurden, V., Stoter, G., Verweij, J.
Publicado 1997

Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in rats.

por van der Zee, J., van den Aardweg, G. J., van Rhoon, G. C., van den Berg, A. P., de Wit, R.
Publicado 1995

External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients

por Vergouwe, Y, Steyerberg, E W, de Wit, R, Roberts, J T, Keizer, H J, Collette, L, Stenning, S P, Habbema, J D F
Publicado 2003

Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Coop...

por de Wit, R., Stoter, G., Sleijfer, D. T., Neijt, J. P., ten Bokkel Huinink, W. W., de Prijck, L., Collette, L., Sylvester, R.
Publicado 1998

The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial

por Rutten, V. C., Salhi, Y., Robbrecht, G. J., de Wit, R., van Leenders, G. J.L.H., Zuiverloon, T. C.M., Boormans, J. L.
Publicado 2023

Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles.

por de Wit, R., van den Berg, H., Burghouts, J., Nortier, J., Slee, P., Rodenburg, C., Keizer, J., Fonteyn, M., Verweij, J., Wils, J.
Publicado 1998

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

por van der Burg, M E L, de Wit, R, van Putten, W L J, Logmans, A, Kruit, W H J, Stoter, G, Verweij, J
Publicado 2002

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tra...

por de Wit, R., Stoter, G., Sleijfer, D. T., Kaye, S. B., de Mulder, P. H., ten Bokkel Huinink, W. W., Spaander, P. J., de Pauw, M., Sylvester, R.
Publicado 1995

Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948)

por Fosså, S D, Paluchowska, B, Horwich, A, Kaiser, G, de Mulder, P H M, Koriakine, O, van Oosterom, A T, de Prijck, L, Collette, L, de Wit, R
Publicado 2005

Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance.

por de Wit, R., Collette, L., Sylvester, R., de Mulder, P. H., Sleijfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Stoter, G.
Publicado 1998

Tumour marker concentration at the start of chemotherapy is a stronger predictor of treatment failure than marker half-life: a study in patients with disseminated non-seminomatous...

por de Wit, R., Sylvester, R., Tsitsa, C., de Mulder, P. H., Sleyfer, D. T., ten Bokkel Huinink, W. W., Kaye, S. B., van Oosterom, A. T., Boven, E., Vermeylen, K., Stoter, G.
Publicado 1997

A phase I/II study of multicyclic dose-intensive chemotherapy supported with G-CSF, or G-CSF and haematopoietic progenitor cells in whole blood, in two consecutive cohorts of patie...

por de Wit, R., Kruit, W. H., Lamers, C. H., van 't Veer, M. B., Luyten, A. A., van Beurden, V., Harteveld, M., Planting, A. S., Schmitz, P. I., Stoter, G., Bolhuis, R. L., Verweij, J.
Publicado 1998